<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20191223045865N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-06-19</date_registration>
      <primary_sponsor>Bojnourd University of Medical Sciences</primary_sponsor>
      <public_title>The effect of probiotics on lupus</public_title>
      <acronym></acronym>
      <scientific_title>The effect of treatment with probiotics on modulating autoimmune inflammation in patients with systemic lupus erythematosus</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-06-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>23</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/70735</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization: In this study, Block Randomization method with 13 blocks size 4 will be used. We will use Excel software and function (rand) to prepare random sequences.
The steps of doing randomization using Excel:
1.	Make a column group with A,A,B,B,C,C
2.	In another column: =rand(). Assign random numbers to each letter. While doing this, use "paste values" to stop recalculating the randomization.
=rand()
3.	Sorting. Sort the random numbers from the lowest to the highest with selecting expand selection.
4.	Sequence. Copy group column and paste it in sequence.
5.	Repeat above steps 11 times And a repeat with block size 2.
6.	Finish. Save the record.

Concealment: A specific numerical code will be assigned to each of the randomly created sequences. Randomization will be done by the study epidemiologist and information will be only given to a study staff at the time of initiation of the intervention, Blinding description: This study is a double-blind randomized clinical trial, in other words, in this study, the researcher and the patient do not know the type of drug used (probiotic and placebo). In this study, drugs are sent in two separate boxes with codes A and B. The nature of the boxes will be reported only after taking the drug and collecting clinical and laboratory data.</study_design>
      <phase>3</phase>
      <hc_freetext>Systemic lupus erythematosus (SLE).</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In addition to common treatments for systemic lupus erythematosus, this group is given three probiotics Lactobacillus roteri, Lactobacillus rhamnosus and Bifidobacterium in a capsule daily. The duration of the intervention is 2 months. Intervention 2: Control group:  In addition to common treatments for systemic lupus erythematosus, this group instead of probiotics placebo is given in a capsule daily. The duration of the intervention is 2 months.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data will be shared, including the amount of medication, duration of medication use, and all outcomes.

When:
All data will be published after the study is done

To whom:
Data will be made available to all researchers upon request

Conditions:
Analyzed data and clinical results of treatment effect in patients are accessible

Where to obtain:
Clinical trial registrar

How to obtain:
Request from the trial registrar by email

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Bojnourd University of Medical Sciences</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Central Building of North Khorasan University of Medical Sciences, Dolat Blvd, Bojnourd</address>
        <city>Bojnourd</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>74877-94149</zip>
        <telephone>+98 58 3151 0000</telephone>
        <email>Mehdi.barati10@yahoo.com</email>
        <affiliation>Bojnourd University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Medhdi Barati</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Central Building of North Khorasan University of Medical Sciences, Dolat Blvd, Bojnourd</address>
        <city>Bojnourd</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>74877-94149</zip>
        <telephone>+98 58 3151 0000</telephone>
        <email>Mehdi.barati10@yahoo.com</email>
        <affiliation>Bojnourd University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Men and women with mild to moderate systemic lupus erythematosus based on Systemic Lupus Erythematosus Disease Activity Index score</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>55 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>The patient did not receive antibacterial medication at the time of the studyPatients with lupus and no underlying disease such as kidney transplant who receive immunosuppressive drugs other than systemic lupus erythematosus for any reason.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M32</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Systemic lupus erythematosus (SLE)</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In addition to common treatments for systemic lupus erythematosus, this group is given three probiotics Lactobacillus roteri, Lactobacillus rhamnosus and Bifidobacterium in a capsule daily. The duration of the intervention is 2 months.</i_keyword>
      <i_keyword>Control group:  In addition to common treatments for systemic lupus erythematosus, this group instead of probiotics placebo is given in a capsule daily. The duration of the intervention is 2 months.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Interleukin 10. Timepoint: In this study, blood is taken from the patient before starting the treatment, and then treatment with probiotics is started. Probiotic treatment is done for two months, and then blood is taken from the patient once again and interleukin 10 is measured. Method of measurement: ELISA.</prim_outcome>
      <prim_outcome>Transforming Growth Factor-β. Timepoint: In this study, blood is taken from the patient before starting the treatment, and then treatment with probiotics is started. Probiotic treatment is done for two months, and then blood is taken from the patient once again and TGF-b is measured. Method of measurement: ELISA.</prim_outcome>
      <prim_outcome>Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). Timepoint: In this study, before the start of the treatment, blood is taken from the patient and the SLE disease activity indedx (SLAEDAI) questionnaire is completed, and then the treatment with pobiotics is started, probiotic treatment is carried out for two months, and then the SLEDAI questionnaire is completed once again. Method of measurement: Questionnaire SELDAI K2000.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Bojnourd University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-05-18</approval_date>
        <contact_name>Ethical committee of North Khorasan University of Medical Sciences</contact_name>
        <contact_address>Dolat Blvd Bojnourd North Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
